{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T15:17:54Z","timestamp":1785597474981,"version":"3.56.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,7,30]],"date-time":"2013-07-30T00:00:00Z","timestamp":1375142400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1038\/nrneph.2013.144","type":"journal-article","created":{"date-parts":[[2013,7,30]],"date-time":"2013-07-30T07:04:56Z","timestamp":1375167896000},"page":"529-538","source":"Crossref","is-referenced-by-count":59,"title":["Renal cancer in von Hippel\u2013Lindau disease and related syndromes"],"prefix":"10.1038","volume":"9","author":[{"given":"Birke","family":"Bausch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cordula","family":"Jilg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Gl\u00e4sker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Vortmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"L\u00fctzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Anton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charis","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut P. H.","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,30]]},"reference":[{"key":"BFnrneph2013144_CR1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","volume":"46","author":"J Ferlay","year":"2010","unstructured":"Ferlay, J., Parkin, D. M. & Steliarova-Foucher, E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46, 765\u2013781 (2010).","journal-title":"Eur. J. Cancer"},{"key":"BFnrneph2013144_CR2","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1001\/jama.281.17.1628","volume":"281","author":"WH Chow","year":"1999","unstructured":"Chow, W. H., Devesa, S. S., Warren, J. L. & Fraumeni, J. F. Jr. Rising incidence of renal cell cancer in the United States. JAMA 281, 1628\u20131631 (1999).","journal-title":"JAMA"},{"key":"BFnrneph2013144_CR3","first-page":"1139","volume-title":"Cancer: Principles & Practice of Oncology","author":"WM Linehan","year":"2005","unstructured":"Linehan, W. M., Yang, J. C. & Bates, S. E. Cancer of the kidney. In Cancer: Principles & Practice of Oncology (eds DeVita, S. E., Hellman, S. & Rosenberg, S. A.) 1139\u20131168 (Lippincott Williams & Wilkins, 2005)."},{"key":"BFnrneph2013144_CR4","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.eururo.2012.09.037","volume":"63","author":"L Tosco","year":"2013","unstructured":"Tosco, L., Van Poppel, H., Frea, B., Gregoraci, G. & Joniau, S. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma. Eur. Urol. 63, 646\u2013652 (2013).","journal-title":"Eur. Urol."},{"key":"BFnrneph2013144_CR5","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJM199609193351207","volume":"335","author":"RJ Motzer","year":"1996","unstructured":"Motzer, R. J., Bander, N. H. & Nanus, D. M. Renal-cell carcinoma. N. Engl. J. Med. 335, 865\u2013875 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013144_CR6","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1097\/01.ju.0000096060.92397.ed","volume":"170","author":"WM Linehan","year":"2003","unstructured":"Linehan, W. M., Walther, M. M. & Zbar, B. The genetic basis of cancer of the kidney. J. Urol. 170, 2163\u20132172 (2003).","journal-title":"J. Urol."},{"key":"BFnrneph2013144_CR7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2362.2010.02270.x","volume":"40","author":"PH Axwijk","year":"2010","unstructured":"Axwijk, P. H.  et al. Hereditary causes of kidney tumours. Eur. J. Clin. Invest. 40, 433\u2013439 (2010).","journal-title":"Eur. J. Clin. Invest."},{"key":"BFnrneph2013144_CR8","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1086\/301888","volume":"62","author":"D Bodmer","year":"1998","unstructured":"Bodmer, D.  et al. An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation. Am. J. Hum. Genet. 62, 1475\u20131483 (1998).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrneph2013144_CR9","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ng1048","volume":"32","author":"JD Carpten","year":"2002","unstructured":"Carpten, J. D.  et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat. Genet. 32, 676\u2013680 (2002).","journal-title":"Nat. Genet."},{"key":"BFnrneph2013144_CR10","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1056\/NEJM197909133011107","volume":"301","author":"AJ Cohen","year":"1979","unstructured":"Cohen, A. J.  et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N. Engl. J. Med. 301, 592\u2013595 (1979).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013144_CR11","first-page":"1758","volume":"85","author":"CD Malchoff","year":"2000","unstructured":"Malchoff, C. D.  et al. Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J. Clin. Endocrinol. Metab. 85, 1758\u20131764 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrneph2013144_CR12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1530\/ERC-11-0324","volume":"19","author":"A Malinoc","year":"2012","unstructured":"Malinoc, A.  et al. Biallelic inactivation of the SDHC gene in renal carcinoma associated with paraganglioma syndrome type 3. Endocr. Relat. Cancer 19, 283\u2013290 (2012).","journal-title":"Endocr. Relat. Cancer"},{"key":"BFnrneph2013144_CR13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1535-6108(02)00104-6","volume":"2","author":"ML Nickerson","year":"2002","unstructured":"Nickerson, M. L.  et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2, 157\u2013164 (2002).","journal-title":"Cancer Cell"},{"key":"BFnrneph2013144_CR14","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/jnci\/djn254","volume":"100","author":"C Ricketts","year":"2008","unstructured":"Ricketts, C.  et al. Germline SDHB mutations and familial renal cell carcinoma. J. Natl Cancer Inst. 100, 1260\u20131262 (2008).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrneph2013144_CR15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/humu.21136","volume":"31","author":"CJ Ricketts","year":"2010","unstructured":"Ricketts, C. J.  et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum. Mutat. 31, 41\u201351 (2010).","journal-title":"Hum. Mutat."},{"key":"BFnrneph2013144_CR16","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/j.juro.2012.08.030","volume":"188","author":"CJ Ricketts","year":"2012","unstructured":"Ricketts, C. J.  et al. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J. Urol. 188, 2063\u20132071 (2012).","journal-title":"J. Urol."},{"key":"BFnrneph2013144_CR17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng0597-68","volume":"16","author":"L Schmidt","year":"1997","unstructured":"Schmidt, L.  et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16, 68\u201373 (1997).","journal-title":"Nat. Genet."},{"key":"BFnrneph2013144_CR18","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng849","volume":"30","author":"IP Tomlinson","year":"2002","unstructured":"Tomlinson, I. P.  et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30, 406\u2013410 (2002).","journal-title":"Nat. Genet."},{"key":"BFnrneph2013144_CR19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1086\/381054","volume":"74","author":"S Vanharanta","year":"2004","unstructured":"Vanharanta, S.  et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am. J. Hum. Genet. 74, 153\u2013159 (2004).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrneph2013144_CR20","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2214\/ajr.159.6.1442389","volume":"159","author":"PL Choyke","year":"1992","unstructured":"Choyke, P. L.  et al. The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients. AJR Am. J. Roentgenol. 159, 1229\u20131234 (1992).","journal-title":"AJR Am. J. Roentgenol."},{"key":"BFnrneph2013144_CR21","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","volume":"361","author":"RR Lonser","year":"2003","unstructured":"Lonser, R. R.  et al. von Hippel-Lindau disease. Lancet 361, 2059\u20132067 (2003).","journal-title":"Lancet"},{"key":"BFnrneph2013144_CR22","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0022-5347(01)62509-6","volume":"160","author":"HP Neumann","year":"1998","unstructured":"Neumann, H. P.  et al. Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma. J. Urol. 160, 1248\u20131254 (1998).","journal-title":"J. Urol."},{"key":"BFnrneph2013144_CR23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00005392-199501000-00009","volume":"153","author":"CD Poston","year":"1995","unstructured":"Poston, C. D.  et al. Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. J. Urol. 153, 22\u201326 (1995).","journal-title":"J. Urol."},{"key":"BFnrneph2013144_CR24","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/PAS.0b013e318227e7f4","volume":"35","author":"AJ Gill","year":"2011","unstructured":"Gill, A. J.  et al. Renal tumors associated with germline SDHB mutation show distinctive morphology. Am. J. Surg. Pathol. 35, 1578\u20131585 (2011).","journal-title":"Am. J. Surg. Pathol."},{"key":"BFnrneph2013144_CR25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/jmedgenet-2011-100562","volume":"49","author":"A Wilding","year":"2012","unstructured":"Wilding, A.  et al. Life expectancy in hereditary cancer predisposing diseases: an observational study. J. Med. Genet. 49, 264\u2013269 (2012).","journal-title":"J. Med. Genet."},{"key":"BFnrneph2013144_CR26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/ng0594-85","volume":"7","author":"JR Gnarra","year":"1994","unstructured":"Gnarra, J. R.  et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85\u201390 (1994).","journal-title":"Nat. Genet."},{"key":"BFnrneph2013144_CR27","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2004.05.061","volume":"22","author":"WY Kim","year":"2004","unstructured":"Kim, W. Y. & Kaelin, W. G. Role of VHL gene mutation in human cancer. J. Clin. Oncol. 22, 4991\u20135004 (2004).","journal-title":"J. Clin. Oncol."},{"key":"BFnrneph2013144_CR28","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.8493574","volume":"260","author":"F Latif","year":"1993","unstructured":"Latif, F.  et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260, 1317\u20131320 (1993).","journal-title":"Science"},{"key":"BFnrneph2013144_CR29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/jmg.28.7.443","volume":"28","author":"ER Maher","year":"1991","unstructured":"Maher, E. R.  et al. Von Hippel-Lindau disease: a genetic study. J. Med. Genet. 28, 443\u2013447 (1991).","journal-title":"J. Med. Genet."},{"key":"BFnrneph2013144_CR30","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/0140-6736(91)91705-Y","volume":"337","author":"HP Neumann","year":"1991","unstructured":"Neumann, H. P. & Wiestler, O. D. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet 337, 1052\u20131054 (1991).","journal-title":"Lancet"},{"key":"BFnrneph2013144_CR31","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/qjmed\/77.2.1151","volume":"77","author":"ER Maher","year":"1990","unstructured":"Maher, E. R.  et al. Clinical features and natural history of von Hippel-Lindau disease. Q. J. Med. 77, 1151\u20131163 (1990).","journal-title":"Q. J. Med."},{"key":"BFnrneph2013144_CR32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/jmg.33.2.120","volume":"33","author":"IR Maddock","year":"1996","unstructured":"Maddock, I. R.  et al. A genetic register for von Hippel-Lindau disease. J. Med. Genet. 33, 120\u2013127 (1996).","journal-title":"J. Med. Genet."},{"key":"BFnrneph2013144_CR33","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/00005792-199711000-00001","volume":"76","author":"ER Maher","year":"1997","unstructured":"Maher, E. R. & Kaelin, W. G. Jr. von Hippel-Lindau disease. Medicine (Baltimore) 76, 381\u2013391 (1997).","journal-title":"Medicine (Baltimore)"},{"key":"BFnrneph2013144_CR34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10689-004-5347-6","volume":"4","author":"S Glasker","year":"2005","unstructured":"Glasker, S. Central nervous system manifestations in VHL: genetics, pathology and clinical phenotypic features. Fam. Cancer 4, 37\u201342 (2005).","journal-title":"Fam. Cancer"},{"key":"BFnrneph2013144_CR35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10689-004-1327-0","volume":"4","author":"KM Kreusel","year":"2005","unstructured":"Kreusel, K. M. Ophthalmological manifestations in VHL and NF 1: pathological and diagnostic implications. Fam. Cancer 4, 43\u201347 (2005).","journal-title":"Fam. Cancer"},{"key":"BFnrneph2013144_CR36","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.ophtha.2006.02.059","volume":"113","author":"KM Kreusel","year":"2006","unstructured":"Kreusel, K. M., Bechrakis, N. E., Krause, L., Neumann, H. P. & Foerster, M. H. Retinal angiomatosis in von Hippel-Lindau disease: a longitudinal ophthalmologic study. Ophthalmology 113, 1418\u20131424 (2006).","journal-title":"Ophthalmology"},{"key":"BFnrneph2013144_CR37","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0022-5347(01)66674-6","volume":"154","author":"MM Walther","year":"1995","unstructured":"Walther, M. M., Lubensky, I. A., Venzon, D., Zbar, B. & Linehan, W. M. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J. Urol. 154, 2010\u20132014 (1995).","journal-title":"J. Urol."},{"key":"BFnrneph2013144_CR38","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/PAS.0b013e3181ddf54d","volume":"34","author":"M Montani","year":"2010","unstructured":"Montani, M.  et al. VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. Am. J. Surg. Pathol. 34, 806\u2013815 (2010).","journal-title":"Am. J. Surg. Pathol."},{"key":"BFnrneph2013144_CR39","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/ncb1579","volume":"9","author":"CR Thoma","year":"2007","unstructured":"Thoma, C. R.  et al. pVHL and GSK3beta are components of a primary cilium-maintenance signalling network. Nat. Cell Biol. 9, 588\u2013595 (2007).","journal-title":"Nat. Cell Biol."},{"key":"BFnrneph2013144_CR40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000333348","volume":"88","author":"CA Jilg","year":"2011","unstructured":"Jilg, C. A.  et al. Growth kinetics in von Hippel-Lindau-associated renal cell carcinoma. Urol. Int. 88, 71\u201378 (2011).","journal-title":"Urol. Int."},{"key":"BFnrneph2013144_CR41","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0022-5347(05)68930-6","volume":"161","author":"MM Walther","year":"1999","unstructured":"Walther, M. M.  et al. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J. Urol. 161, 1475\u20131479 (1999).","journal-title":"J. Urol."},{"key":"BFnrneph2013144_CR42","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(02)00071-5","volume":"1","author":"SJ Mandriota","year":"2002","unstructured":"Mandriota, S. J.  et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1, 459\u2013468 (2002).","journal-title":"Cancer Cell"},{"key":"BFnrneph2013144_CR43","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s11255-007-9308-5","volume":"40","author":"S Akcaglar","year":"2008","unstructured":"Akcaglar, S., Yavascaoglu, I., Vuruskan, H. & Oktay, B. Genetic evaluation of von Hippel-Lindau disease for early diagnosis and improved prognosis. Int. Urol. Nephrol. 40, 615\u2013620 (2008).","journal-title":"Int. Urol. Nephrol."},{"key":"BFnrneph2013144_CR44","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s004390000265","volume":"106","author":"F Hes","year":"2000","unstructured":"Hes, F.  et al. Genotype-phenotype correlations in families with deletions in the von Hippel-Lindau (VHL) gene. Hum. Genet. 106, 425\u2013431 (2000).","journal-title":"Hum. Genet."},{"key":"BFnrneph2013144_CR45","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc885","volume":"2","author":"WG Kaelin Jr.","year":"2002","unstructured":"Kaelin, W. G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2, 673\u2013682 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrneph2013144_CR46","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3","volume":"8","author":"B Zbar","year":"1996","unstructured":"Zbar, B.  et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum. Mutat. 8, 348\u2013357 (1996).","journal-title":"Hum. Mutat."},{"key":"BFnrneph2013144_CR47","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/humu.10302","volume":"23","author":"JK Maranchie","year":"2004","unstructured":"Maranchie, J. K.  et al. Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum. Mutat. 23, 40\u201346 (2004).","journal-title":"Hum. Mutat."},{"key":"BFnrneph2013144_CR48","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ajmg.a.33023","volume":"149A","author":"A McNeill","year":"2009","unstructured":"McNeill, A.  et al. Genotype-phenotype correlations in VHL exon deletions. Am J. Med. Genet. A 149A, 2147\u20132151 (2009).","journal-title":"Am J. Med. Genet. A"},{"key":"BFnrneph2013144_CR49","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1470-2045(10)70007-3","volume":"11","author":"JP Bayley","year":"2010","unstructured":"Bayley, J. P.  et al. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol. 11, 366\u2013372 (2010).","journal-title":"Lancet Oncol."},{"key":"BFnrneph2013144_CR50","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1126\/science.1175689","volume":"325","author":"HX Hao","year":"2009","unstructured":"Hao, H. X.  et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 325, 1139\u20131142 (2009).","journal-title":"Science"},{"key":"BFnrneph2013144_CR51","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1136\/jmg.2007.051045","volume":"44","author":"M Mannelli","year":"2007","unstructured":"Mannelli, M.  et al. Genetic screening for pheochromocytoma: should SDHC gene analysis be included? J. Med. Genet. 44, 586\u2013587 (2007).","journal-title":"J. Med. Genet."},{"key":"BFnrneph2013144_CR52","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJMoa020152","volume":"346","author":"HP Neumann","year":"2002","unstructured":"Neumann, H. P.  et al. Germ-line mutations in nonsyndromic pheochromocytoma. N. Engl. J. Med. 346, 1459\u20131466 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013144_CR53","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.292.8.943","volume":"292","author":"HP Neumann","year":"2004","unstructured":"Neumann, H. P.  et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292, 943\u2013951 (2004).","journal-title":"JAMA"},{"key":"BFnrneph2013144_CR54","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1001\/jama.294.16.2057","volume":"294","author":"F Schiavi","year":"2005","unstructured":"Schiavi, F.  et al. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA 294, 2057\u20132063 (2005).","journal-title":"JAMA"},{"key":"BFnrneph2013144_CR55","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1056\/NEJMc066006","volume":"354","author":"B Bausch","year":"2006","unstructured":"Bausch, B., Borozdin, W. & Neumann, H. P. Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. N. Engl. J. Med. 354, 2729\u20132731 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013144_CR56","first-page":"917","volume":"23","author":"MJ Merino","year":"2010","unstructured":"Merino, M. J., Parillar-Castella, E. R., Linehan, M. The unrecognised morphology of renal tumours in SDH syndromes: immunohistochemistry and genetic changes [abstract]. Mod. Pathol. 23, 917 (2010).","journal-title":"Mod. Pathol."},{"key":"BFnrneph2013144_CR57","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMc1012357","volume":"364","author":"AJ Gill","year":"2011","unstructured":"Gill, A. J.  et al. Renal tumors and hereditary pheochromocytoma-paraganglioma syndrome type 4. N. Engl. J. Med. 364, 885\u2013886 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013144_CR58","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.juro.2007.01.155","volume":"177","author":"RL Grubb 3rd","year":"2007","unstructured":"Grubb, R. L. 3rd  et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J. Urol. 177, 2074\u20132079 (2007).","journal-title":"J. Urol."},{"key":"BFnrneph2013144_CR59","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S1535-6108(02)00043-0","volume":"1","author":"K Kondo","year":"2002","unstructured":"Kondo, K., Klco, J., Nakamura, E., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1, 237\u2013246 (2002).","journal-title":"Cancer Cell"},{"key":"BFnrneph2013144_CR60","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"PH Maxwell","year":"1999","unstructured":"Maxwell, P. H.  et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271\u2013275 (1999).","journal-title":"Nature"},{"key":"BFnrneph2013144_CR61","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ccr.2005.06.017","volume":"8","author":"JS Isaacs","year":"2005","unstructured":"Isaacs, J. S.  et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8, 143\u2013153 (2005).","journal-title":"Cancer Cell"},{"key":"BFnrneph2013144_CR62","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","volume":"7","author":"MA Selak","year":"2005","unstructured":"Selak, M. A.  et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7, 77\u201385 (2005).","journal-title":"Cancer Cell"},{"key":"BFnrneph2013144_CR63","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.hoc.2011.04.004","volume":"25","author":"L Li","year":"2011","unstructured":"Li, L. & Kaelin, W. G. Jr. New insights into the biology of renal cell carcinoma. Hematol. Oncol. Clin. North Am. 25, 667\u2013686 (2011).","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"BFnrneph2013144_CR64","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer, R. J.  et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449\u2013456 (2008).","journal-title":"Lancet"},{"key":"BFnrneph2013144_CR65","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes, G.  et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271\u20132281 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013144_CR66","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier, B.  et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125\u2013134 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013144_CR67","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer, R. J.  et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115\u2013124 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013144_CR68","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1464-410X.2011.10629.x","volume":"108","author":"C Coppin","year":"2011","unstructured":"Coppin, C., Kollmannsberger, C., Le, L., Porzsolt, F. & Wilt, T. J. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int. 108, 1556\u20131563 (2011).","journal-title":"BJU Int."},{"key":"BFnrneph2013144_CR69","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.eururo.2011.06.029","volume":"60","author":"E Guethmundsson","year":"2011","unstructured":"Guethmundsson, E., Hellborg, H., Lundstam, S., Erikson, S. & Ljungberg, B. Metastatic potential in renal cell carcinomas \u22647 cm: Swedish Kidney Cancer Quality Register data. Eur. Urol. 60, 975\u2013982 (2011).","journal-title":"Eur. Urol."},{"key":"BFnrneph2013144_CR70","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.juro.2008.03.030","volume":"180","author":"A Johnson","year":"2008","unstructured":"Johnson, A.  et al. Feasibility and outcomes of repeat partial nephrectomy. J. Urol. 180, 89\u201393 (2008).","journal-title":"J. Urol."},{"key":"BFnrneph2013144_CR71","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0022-5347(05)66524-X","volume":"165","author":"JC Herring","year":"2001","unstructured":"Herring, J. C.  et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J. Urol. 165, 777\u2013781 (2001).","journal-title":"J. Urol."},{"key":"BFnrneph2013144_CR72","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/01.ju.0000132127.79974.3f","volume":"172","author":"BG Duffey","year":"2004","unstructured":"Duffey, B. G.  et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J. Urol. 172, 63\u201365 (2004).","journal-title":"J. Urol."},{"key":"BFnrneph2013144_CR73","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.urology.2007.04.040","volume":"70","author":"G Ploussard","year":"2007","unstructured":"Ploussard, G.  et al. Local recurrence after nephron-sparing surgery in von Hippel-Lindau disease. Urology 70, 435\u2013439 (2007).","journal-title":"Urology"},{"key":"BFnrneph2013144_CR74","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/j.1464-410X.2008.07718.x","volume":"102","author":"SF Matin","year":"2008","unstructured":"Matin, S. F., Ahrar, K., Wood, C. G., Daniels, M. & Jonasch, E. Patterns of intervention for renal lesions in von Hippel-Lindau disease. BJU Int. 102, 940\u2013945 (2008).","journal-title":"BJU Int."},{"key":"BFnrneph2013144_CR75","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1016\/j.juro.2011.02.007","volume":"185","author":"D Joly","year":"2011","unstructured":"Joly, D.  et al. Progress in nephron sparing therapy for renal cell carcinoma and von Hippel-Lindau disease. J. Urol. 185, 2056\u20132060 (2011).","journal-title":"J. Urol."},{"key":"BFnrneph2013144_CR76","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10689-012-9525-7","volume":"11","author":"CA Jilg","year":"2012","unstructured":"Jilg, C. A.  et al. Nephron sparing surgery in von Hippel-Lindau associated renal cell carcinoma; clinicopathological long-term follow-up. Fam. Cancer 11, 387\u2013394 (2012).","journal-title":"Fam. Cancer"},{"key":"BFnrneph2013144_CR77","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1097\/01.ju.0000092780.85876.de","volume":"170","author":"M Roupret","year":"2003","unstructured":"Roupret, M.  et al. Nephron sparing surgery for renal cell carcinoma and von Hippel-Lindau's disease: a single center experience. J. Urol. 170, 1752\u20131755 (2003).","journal-title":"J. Urol."},{"key":"BFnrneph2013144_CR78","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.juro.2010.03.035","volume":"184","author":"GN Gupta","year":"2010","unstructured":"Gupta, G. N.  et al. Oncological outcomes of partial nephrectomy for multifocal renal cell carcinoma greater than 4 cm. J. Urol. 184, 59\u201363 (2010).","journal-title":"J. Urol."},{"key":"BFnrneph2013144_CR79","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1258\/ar.2011.100435","volume":"52","author":"SY Park","year":"2011","unstructured":"Park, S. Y.  et al. Percutaneous radiofrequency ablation of renal cell carcinomas in patients with von Hippel Lindau disease previously undergoing a radical nephrectomy or repeated nephron-sparing surgery. Acta Radiol. 52, 680\u2013685 (2011).","journal-title":"Acta Radiol."},{"key":"BFnrneph2013144_CR80","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10689-011-9440-3","volume":"10","author":"Y Iwamoto","year":"2011","unstructured":"Iwamoto, Y.  et al. Management of renal tumors in Von Hippel-Lindau disease by percutaneous CT fluoroscopic guided radiofrequency ablation: preliminary results. Fam. Cancer 10, 529\u2013534 (2011).","journal-title":"Fam. Cancer"},{"key":"BFnrneph2013144_CR81","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.juro.2010.01.022","volume":"183","author":"BK Park","year":"2010","unstructured":"Park, B. K. & Kim, C. K. Percutaneous radio frequency ablation of renal tumors in patients with von Hippel-Lindau disease: preliminary results. J. Urol. 183, 1703\u20131707 (2010).","journal-title":"J. Urol."},{"key":"BFnrneph2013144_CR82","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1097\/00007890-199712270-00017","volume":"64","author":"DA Goldfarb","year":"1997","unstructured":"Goldfarb, D. A., Neumann, H. P., Penn, I. & Novick, A. C. Results of renal transplantation in patients with renal cell carcinoma and von Hippel-Lindau disease. Transplantation 64, 1726\u20131729 (1997).","journal-title":"Transplantation"},{"key":"BFnrneph2013144_CR83","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/j.1523-1755.2005.00309.x","volume":"67","author":"MB Atkins","year":"2005","unstructured":"Atkins, M. B. Management of advanced renal cancer. Kidney Int. 67, 2069\u20132082 (2005).","journal-title":"Kidney Int."},{"key":"BFnrneph2013144_CR84","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/S0140-6736(07)61874-1","volume":"370","author":"RJ Motzer","year":"2007","unstructured":"Motzer, R. J. & Basch, E. Targeted drugs for metastatic renal cell carcinoma. Lancet 370, 2071\u20132073 (2007).","journal-title":"Lancet"},{"key":"BFnrneph2013144_CR85","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.juro.2007.07.030","volume":"178","author":"RJ Motzer","year":"2007","unstructured":"Motzer, R. J.  et al. Sunitinib efficacy against advanced renal cell carcinoma. J. Urol. 178, 1883\u20131887 (2007).","journal-title":"J. Urol."},{"key":"BFnrneph2013144_CR86","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/jjco\/hyl052","volume":"36","author":"T Shuin","year":"2006","unstructured":"Shuin, T.  et al. Von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment. Jpn. J. Clin. Oncol. 36, 337\u2013343 (2006).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"BFnrneph2013144_CR87","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1038\/sj.onc.1207591","volume":"23","author":"EF Hensen","year":"2004","unstructured":"Hensen, E. F.  et al. Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene 23, 4076\u20134083 (2004).","journal-title":"Oncogene"}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2013.144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2013.144","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2013.144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:40:55Z","timestamp":1684471255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2013.144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,30]]},"references-count":87,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["BFnrneph2013144"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2013.144","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,30]]}}}